Status:
COMPLETED
MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Chronic Ischemic Heart Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
Brief Summary
Coronary artery disease (CAD) is the most common cause of death and a major cause of hospital admissions for acute chest pain. In spite of improved treatments still many patients with CAD have daily a...
Detailed Description
In an open single centre pilot study we have evaluated the safety and efficacy of MSC treatment to improve heart muscle perfusion in patients with chronic CAD. Patients treated with MSCs had significa...
Eligibility Criteria
Inclusion
- CCS III - IV
- Coronary artery stenosis/occlusion not treatable with invasive procedures
- LVEF \> 40%
- ETT between 2 - 10 min
Exclusion
- Valvular heart disease
- FEV1 \< 1
- Severe systemic disease
- Acute coronary syndrome \> 2 months
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01449032
Start Date
April 1 2010
End Date
January 1 2014
Last Update
June 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet University Hospital Copenhagen
Copenhagen, Denmark, 210